Ozempic vs Wegovy: Same Molecule, Different Licence

Ozempic and Wegovy contain the same medicine, semaglutide, made by the same company, Novo Nordisk. The difference is in how each is licensed and dosed. In the UK, Ozempic is licensed to treat type 2 diabetes, at doses up to 2mg once a week. Wegovy is licensed for weight management, at doses up to 2.4mg once a week (or 7.2mg for some adults with obesity), and to reduce cardiovascular risk in people with established heart disease. The pens, dose steps, evidence base and NHS routes also differ. For weight management, Wegovy is the licensed choice; Ozempic is a diabetes medicine.

Why two brands for one medicine?

Medicines are licensed for specific uses based on the trials that support them. Novo Nordisk first developed once-weekly semaglutide for type 2 diabetes and tested it in the SUSTAIN trial programme. That product became Ozempic, authorised in the UK and EU in 2018.

Researchers saw that people taking semaglutide also lost weight, so the company ran a separate programme of trials, called STEP, testing a higher dose (2.4mg) specifically for weight management in people with and without diabetes. That product became Wegovy, authorised in the UK for weight management in September 2021.

Using separate brands keeps the products distinct for prescribers, pharmacists and patients. It also allows different pens and dose steps tailored to each condition, and separate pricing and supply arrangements.

Side-by-side comparison

Details summarised from the SmPCs and MHRA. Check the current SmPC on medicines.org.uk for exact licence wording.

Doses: why they matter

The most practical difference is dose. Ozempic's highest dose (2mg) is below Wegovy's standard maintenance dose (2.4mg), and well below the 7.2mg dose authorised in January 2026.

Weight loss with GLP-1 medicines is dose-related, at least up to a point. The clearest evidence comes from STEP 2 (The Lancet, 2021), which included adults with overweight or obesity and type 2 diabetes. Participants were randomised to semaglutide 2.4mg, semaglutide 1mg or placebo for 68 weeks.

Both semaglutide doses led to clinically meaningful weight loss, but 2.4mg produced more. Blood glucose improvements were similar between the two doses, which reflects the fact that the diabetes benefits of semaglutide largely plateau at lower doses than its weight effects.

For comparison, people without diabetes typically lose more weight on GLP-1 medicines. In STEP 1, adults without diabetes lost an average of 14.9% on 2.4mg over 68 weeks. Our Wegovy results guide explains the STEP trials in more detail.

Pens and devices

Both products use pre-filled, multi-dose pens, but they are not the same device.

• Ozempic pens are designed around diabetes dosing. Each pen delivers specific doses, and patients select their dose on the pen.
• Wegovy FlexTouch pens come in five strengths matching the weight-management step-up, and each pen holds four weekly doses. For the 7.2mg dose, three 2.4mg injections are given on the same day.

Because the pens and dose markings differ, people should never try to use an Ozempic pen to deliver a Wegovy dose, or vice versa. Our Wegovy pen guide explains how the FlexTouch pen works.

Evidence base

Ozempic: the SUSTAIN programme

The SUSTAIN trials tested semaglutide in people with type 2 diabetes, comparing it with placebo and with other diabetes medicines. Key findings included lower HbA1c and modest weight loss. SUSTAIN-6 (NEJM, 2016) showed a reduction in major cardiovascular events compared with placebo in people with type 2 diabetes at high cardiovascular risk. Later trials have looked at kidney outcomes in people with diabetes and chronic kidney disease.

Wegovy: the STEP programme and SELECT

The STEP trials tested semaglutide 2.4mg for weight management. STEP 1 (no diabetes) showed 14.9% average weight loss at 68 weeks; STEP 2 (with diabetes) 9.6%; STEP 4 showed weight regain when treatment was withdrawn; STEP 5 showed sustained weight loss over two years. SELECT (NEJM, 2023) showed a 20% relative reduction in major cardiovascular events in people with established cardiovascular disease and a BMI of 27 or more, without diabetes. Our SELECT trial guide covers that study.

Side effects and safety

Since the molecule is the same, the side-effect profiles are very similar. The most common side effects are gastrointestinal:

• nausea
• diarrhoea
• vomiting
• constipation
• abdominal pain, bloating, burping and indigestion

These tend to be dose-related and most noticeable when the dose is increased. In STEP 2, gastrointestinal side effects were reported somewhat more often with 2.4mg than with 1mg.

Both products carry warnings about gallbladder problems, acute pancreatitis, dehydration and kidney problems, and aspiration under anaesthesia. Semaglutide product information also lists a very rare eye condition, non-arteritic anterior ischaemic optic neuropathy (NAION).

There are some differences in emphasis because of the populations each product treats:

• Hypoglycaemia is a particular concern with Ozempic, because people with diabetes may also take insulin or sulfonylureas.
• Diabetic retinopathy can worsen when blood glucose falls rapidly in people with diabetes and existing retinopathy, which is highlighted in the Ozempic SmPC.
• Altered skin sensation (dysaesthesia) was more common with the 7.2mg Wegovy dose in the STEP UP trial.

Our Wegovy side effects guide and our guide to GLP-1 medication and type 2 diabetes explain management in more detail.

Off-label use and the shortages

"Off-label" means prescribing a medicine outside the terms of its licence. It is legal in the UK in some circumstances, but the prescriber takes on greater responsibility for the decision and should usually only do so when there is no suitable licensed alternative.

During 2023 and 2024, demand for semaglutide outstripped supply. UK health authorities issued alerts advising that GLP-1 medicines licensed for diabetes should only be prescribed for their licensed indication, so that people with type 2 diabetes could keep receiving treatment. Supply has since improved, but the principle remains: with Wegovy licensed for weight management, there is rarely a good reason to prescribe Ozempic for that purpose.

Regulated UK online pharmacies are expected to follow General Pharmaceutical Council (GPhC) guidance, which includes extra safeguards for weight-management medicines such as verifying identity and weight. A service offering Ozempic for weight loss with minimal checks should be treated with caution. Our guide to getting weight loss injections online safely explains what good practice looks like.

Fake and unlicensed "Ozempic"

Ozempic's name recognition has made it a target for counterfeiters. The MHRA has warned about fake Ozempic pens and unlicensed semaglutide products sold online and through social media. Warning signs include:

• no consultation or prescription required
• products sold as vials, powders or "research peptides"
• unfamiliar packaging or labelling not in English
• unusually low prices
• sellers on social media or messaging apps rather than registered pharmacies

Fake products may contain the wrong dose, a different substance or contaminants, and some have caused serious harm. Our guide to fake weight loss jabs explains how to check a pharmacy is registered.

NHS access

• Ozempic is prescribed on the NHS for type 2 diabetes according to diabetes treatment guidance, usually by a GP or diabetes team.
• Wegovy for weight management is recommended under NICE TA875 within specialist weight management services, for up to two years, for adults who meet BMI and comorbidity criteria. For cardiovascular risk reduction, NICE TA1152 (May 2026) recommends semaglutide for adults with established cardiovascular disease and a BMI of at least 27.

Our guide to Wegovy on the NHS explains eligibility and referral.

If you have type 2 diabetes and want to lose weight

People with type 2 diabetes and overweight or obesity sometimes ask whether they should be on Ozempic or Wegovy. This is a clinical decision that depends on your HbA1c, weight, other medicines, cardiovascular history and NHS eligibility. Some points to discuss with your diabetes team:

• Wegovy is licensed for weight management in adults with or without diabetes; Ozempic is licensed for diabetes.
• Higher semaglutide doses led to more weight loss in STEP 2, with similar glucose control.
• Tirzepatide (Mounjaro) is licensed both for type 2 diabetes and for weight management and may be an alternative. See our Mounjaro vs Wegovy comparison.
• If you are on insulin or a sulfonylurea, your doses may need reducing when starting or increasing a GLP-1 medicine.
• You should not take two GLP-1 medicines at the same time.

Switching between Ozempic and Wegovy

Switching should only happen under a prescriber's guidance. There is no single conversion rule set out for every situation. Your prescriber will consider:

• your current dose and how long you have been on it
• how well you tolerate it
• your reason for switching (for example, weight management, supply, or a change in licence eligibility)
• your diabetes control and other medicines

Because Wegovy's dose steps include 1.7mg and 2.4mg, which Ozempic does not, a prescriber may choose to step you up gradually after switching. If you have had a gap in treatment, you may need to restart at a lower dose.

What about the tablet versions?

The same "same molecule, different licence" pattern applies to oral semaglutide.

• Rybelsus is a once-daily semaglutide tablet licensed for type 2 diabetes. A new formulation (1.5mg, 4mg and 9mg) replaced the original 3mg, 7mg and 14mg tablets in the UK in 2025.
• Wegovy tablets are once-daily semaglutide tablets licensed for weight management, authorised by the MHRA in June 2026. They step up from 1.5mg to 25mg.

As with the injections, the tablets are not interchangeable. Wegovy tablets reach a much higher top dose than Rybelsus, and the two formulations of Rybelsus are not equivalent milligram for milligram. Both must be taken on an empty stomach with a small sip of water, at least 30 minutes before food, drink or other oral medicines. Our guides to oral semaglutide and Rybelsus and weight loss explain the details.

Common misconceptions

"Ozempic is the weight-loss jab and Wegovy is a copy." Both are original Novo Nordisk products. Ozempic came first for diabetes; Wegovy was developed and licensed specifically for weight management.

"Ozempic is stronger because it is better known." The opposite is closer to the truth for weight. Wegovy's maximum dose is higher, and higher semaglutide doses produced more weight loss in trials.

"They are interchangeable, so it does not matter which one I get." They contain the same molecule, but different pens, doses and licences mean they should not be swapped without a prescriber.

"Ozempic face is a special side effect of Ozempic." "Ozempic face" is a popular term for facial volume loss after significant weight loss from any cause. It is not specific to Ozempic. Our guide to facial changes and loose skin explains what is known.

"If it is called Ozempic online, it is genuine." Ozempic is one of the most counterfeited medicine names. Only trust products supplied by a registered UK pharmacy against a valid prescription.

Questions to ask a prescriber

If you are trying to work out which product is relevant to you, these questions may help:

• Is my main goal weight management, blood glucose control, cardiovascular risk reduction, or a combination?
• Which product is licensed for my situation?
• What dose would I start on, and how would it be increased?
• How would my other medicines, especially diabetes medicines, need to change?
• What monitoring would I need, and how often?
• If I already take one semaglutide product, should I switch, and how?

Cost

Ozempic is supplied on the NHS for type 2 diabetes. Private prescribing for weight management is based on Wegovy, and costs depend on the dose, the provider and what is included. We do not quote prices in our guides because they change frequently; our prices page explains the factors involved, and our provider comparison sets out how services differ.

Related guides

• Semaglutide in the UK: Wegovy, Ozempic and Rybelsus explained
• Wegovy in the UK: the complete guide
• Rybelsus and weight loss
• The Wegovy hub

When to speak to a professional

Speak to your GP, diabetes team, pharmacist or prescriber if:

• You are unsure whether you have been prescribed Ozempic or Wegovy, or which dose.
• You have type 2 diabetes and want to discuss weight-management options.
• You are taking insulin or a sulfonylurea and notice symptoms of low blood sugar, such as shakiness, sweating, confusion or a fast heartbeat.
• You have diabetic retinopathy and notice any change in your vision.
• Side effects are making it hard to eat or drink.
• You have been offered semaglutide without a prescription or consultation.

Seek urgent medical help (NHS 111, or 999 in an emergency) if you have:

• Severe, persistent abdominal pain, which may spread to your back, with or without vomiting (possible pancreatitis).
• Pain in the upper right abdomen with fever or yellowing of the skin or eyes (possible gallbladder problems).
• Persistent vomiting or diarrhoea with signs of dehydration.
• Severe hypoglycaemia, such as confusion, drowsiness or loss of consciousness, in someone taking diabetes medicines.
• Sudden loss of vision or blurred vision in one eye.

Whether Ozempic, Wegovy or another treatment is right for you is a decision for a qualified prescriber.